Osimertinib Regresses an EGFR-Mutant Cisplatinum- Resistant Lung Adenocarcinoma Growing in the Brain in Nude Mice

Takashi Higuchi; Hiromichi Oshiro; Zhiying Zhang; Kentaro Miyake; Norihiko Sugisawa; Yuki Katsuya; Norio Yamamoto; Katsuhiro Hayashi; Hiroaki Kimura; Shinji Miwa; Kentaro Igarashi; Ming Zhao; Michael Bouvet; Shree Ram Singh; Hiroyuki Tsuchiya; Robert M. Hoffman

doi:10.1016/j.tranon.2019.01.007

Osimertinib Regresses an EGFR-Mutant Cisplatinum- Resistant Lung Adenocarcinoma Growing in the Brain in Nude Mice

Takashi Higuchi, Hiromichi Oshiro, Zhiying Zhang, Kentaro Miyake, Norihiko Sugisawa, Yuki Katsuya, Norio Yamamoto, Katsuhiro Hayashi, Hiroaki Kimura, Shinji Miwa, Kentaro Igarashi, Ming Zhao, Michael Bouvet, Shree Ram Singh, Hiroyuki Tsuchiya, Robert M. Hoffman

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

Abstract

The goal of the present study was to determine the efficacy of osimertinib (AZD9291), a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor for the treatment of aggressive EGFR-mutant non-small cell lung cancer (NSCLC), compared to cisplatinum (CDDP) + pemetrexed (PEM). The NSCLC cell line PC-9 expressing green fluorescence protein (PC-9-GFP) was implanted in the brain of nude mice and was treated with CDDP + PEM or AZD9291. Tumors were observed by non-invasive fluorescence imaging. AZD9291 treatment caused tumor regression in contrast to CDDP + PEM which had only a slight inhibitory effect. These results suggest that AZD9291 is a promising clinical option for NSCLC patients with brain metastasis.

Original language	English
Pages (from-to)	640-645
Number of pages	6
Journal	Translational Oncology
Volume	12
Issue number	4
DOIs	https://doi.org/10.1016/j.tranon.2019.01.007
Publication status	Published - 2019 Apr
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.tranon.2019.01.007

Cite this

Higuchi, T., Oshiro, H., Zhang, Z., Miyake, K., Sugisawa, N., Katsuya, Y., Yamamoto, N., Hayashi, K., Kimura, H., Miwa, S., Igarashi, K., Zhao, M., Bouvet, M., Singh, S. R., Tsuchiya, H., & Hoffman, R. M. (2019). Osimertinib Regresses an EGFR-Mutant Cisplatinum- Resistant Lung Adenocarcinoma Growing in the Brain in Nude Mice. Translational Oncology, 12(4), 640-645. https://doi.org/10.1016/j.tranon.2019.01.007

Higuchi, T, Oshiro, H, Zhang, Z, Miyake, K, Sugisawa, N, Katsuya, Y, Yamamoto, N, Hayashi, K, Kimura, H, Miwa, S, Igarashi, K, Zhao, M, Bouvet, M, Singh, SR, Tsuchiya, H & Hoffman, RM 2019, 'Osimertinib Regresses an EGFR-Mutant Cisplatinum- Resistant Lung Adenocarcinoma Growing in the Brain in Nude Mice', Translational Oncology, vol. 12, no. 4, pp. 640-645. https://doi.org/10.1016/j.tranon.2019.01.007

@article{743408c8b3f048758f47a25c013666a7,

title = "Osimertinib Regresses an EGFR-Mutant Cisplatinum- Resistant Lung Adenocarcinoma Growing in the Brain in Nude Mice",

abstract = "The goal of the present study was to determine the efficacy of osimertinib (AZD9291), a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor for the treatment of aggressive EGFR-mutant non-small cell lung cancer (NSCLC), compared to cisplatinum (CDDP) + pemetrexed (PEM). The NSCLC cell line PC-9 expressing green fluorescence protein (PC-9-GFP) was implanted in the brain of nude mice and was treated with CDDP + PEM or AZD9291. Tumors were observed by non-invasive fluorescence imaging. AZD9291 treatment caused tumor regression in contrast to CDDP + PEM which had only a slight inhibitory effect. These results suggest that AZD9291 is a promising clinical option for NSCLC patients with brain metastasis.",

author = "Takashi Higuchi and Hiromichi Oshiro and Zhiying Zhang and Kentaro Miyake and Norihiko Sugisawa and Yuki Katsuya and Norio Yamamoto and Katsuhiro Hayashi and Hiroaki Kimura and Shinji Miwa and Kentaro Igarashi and Ming Zhao and Michael Bouvet and Singh, {Shree Ram} and Hiroyuki Tsuchiya and Hoffman, {Robert M.}",

note = "Publisher Copyright: {\textcopyright} 2019",

year = "2019",

month = apr,

doi = "10.1016/j.tranon.2019.01.007",

language = "English",

volume = "12",

pages = "640--645",

journal = "Translational Oncology",

issn = "1936-5233",

publisher = "Neoplasia Press",

number = "4",

}

TY - JOUR

T1 - Osimertinib Regresses an EGFR-Mutant Cisplatinum- Resistant Lung Adenocarcinoma Growing in the Brain in Nude Mice

AU - Higuchi, Takashi

AU - Oshiro, Hiromichi

AU - Zhang, Zhiying

AU - Miyake, Kentaro

AU - Sugisawa, Norihiko

AU - Katsuya, Yuki

AU - Yamamoto, Norio

AU - Hayashi, Katsuhiro

AU - Kimura, Hiroaki

AU - Miwa, Shinji

AU - Igarashi, Kentaro

AU - Zhao, Ming

AU - Bouvet, Michael

AU - Singh, Shree Ram

AU - Tsuchiya, Hiroyuki

AU - Hoffman, Robert M.

PY - 2019/4

Y1 - 2019/4

N2 - The goal of the present study was to determine the efficacy of osimertinib (AZD9291), a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor for the treatment of aggressive EGFR-mutant non-small cell lung cancer (NSCLC), compared to cisplatinum (CDDP) + pemetrexed (PEM). The NSCLC cell line PC-9 expressing green fluorescence protein (PC-9-GFP) was implanted in the brain of nude mice and was treated with CDDP + PEM or AZD9291. Tumors were observed by non-invasive fluorescence imaging. AZD9291 treatment caused tumor regression in contrast to CDDP + PEM which had only a slight inhibitory effect. These results suggest that AZD9291 is a promising clinical option for NSCLC patients with brain metastasis.

AB - The goal of the present study was to determine the efficacy of osimertinib (AZD9291), a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor for the treatment of aggressive EGFR-mutant non-small cell lung cancer (NSCLC), compared to cisplatinum (CDDP) + pemetrexed (PEM). The NSCLC cell line PC-9 expressing green fluorescence protein (PC-9-GFP) was implanted in the brain of nude mice and was treated with CDDP + PEM or AZD9291. Tumors were observed by non-invasive fluorescence imaging. AZD9291 treatment caused tumor regression in contrast to CDDP + PEM which had only a slight inhibitory effect. These results suggest that AZD9291 is a promising clinical option for NSCLC patients with brain metastasis.

UR - http://www.scopus.com/inward/record.url?scp=85061836660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061836660&partnerID=8YFLogxK

U2 - 10.1016/j.tranon.2019.01.007

DO - 10.1016/j.tranon.2019.01.007

M3 - Article

AN - SCOPUS:85061836660

SN - 1936-5233

VL - 12

SP - 640

EP - 645

JO - Translational Oncology

JF - Translational Oncology

IS - 4

ER -

Osimertinib Regresses an EGFR-Mutant Cisplatinum- Resistant Lung Adenocarcinoma Growing in the Brain in Nude Mice

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this